Company
Cabaletta Bio
Composing Cell Therapy Approaches in Autoimmunity
- Business model
- B2B
- Legal name
- Cabaletta Bio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Cabaletta Bio (CABA) is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases
Funding snapshot
- Total raised
- $88.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $50M2019-01-02
Funding rounds
- Round, 2019
- $50M2019-01-02, SEC form D sold, 16 investors
- Round, 2018
- $38.3M2018-10-10, SEC form D sold, 11 investors
Products
- Web
- rese-cel
Loading relationship preview